November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003

Dec 2, 2022 | Deal of the Month, Partnership Deals

November 2022 Top Biopharma Deal Upfront
POINT development and commercialization deal with Lantheus for PNT2002 and PNT2003

Highlighted Deal Financial Comps

Date Announced:

November 11, 2022

Total Deal Value:


Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

$1,871M dev. and sales milestones


20% royalty for PNT2002 and 15% royalty for PNT2003

Cost & Profit Split:


Deal Synopsis

The Asset:

POINT’s PNT2002, a PSMA-targeted 177 Lu-based radiopharmaceutical therapy for mCRPC, and PNT2003, a somatostatin receptor (SSTR) targeted radioligand therapy for GEP-NETs

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development, Shared Dev Cost

Deal Details:

  • POINT granted Lantheus exclusive, worldwide ex-Asia rights to co-develop and commercialize POINT’s PNT2002, a PSMA-targeted 177 Lu-based radiopharmaceutical therapy, and PNT2003, a somatostatin receptor (SSTR) targeted radioligand therapy by combining POINT’s radioligand development expertise with Lantheus’ commercial expertise in PSMA PET and radiopharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  • POINT will be responsible for the funding, development, and manufacturing of PNT2002 and PNT2003 while Lantheus will be responsible for NDA approval and development and commercial expenses.
  • POINT will receive $250M and $10M up front and is eligible for up to $281M and $34.5M in development milestones and up to $1.28B and $275M in commercial milestones, plus 20% and 15% royalties for PNT2002 and PNT2003 respectively.

Last Month:

Congrats to POINT and Lantheus for landing DealForma’s November 2022 Top Biopharma Deal. Last month’s Deal of the Month was MacroGenics – Gilead for mCRPC and GEP-NETs drug PNT2002 and PNT2003. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Introducing: DealForma plus Tableau

Introducing: DealForma plus Tableau

We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...

Venture & IPO – Medtech – Q1 2023 

Venture & IPO – Medtech – Q1 2023 

The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...